European Patent Office Approves Two Breakthrough AI and Microbiome Patent Applications for Human Biome
The European Patent Office Approves Two of Our Patent Applications Covering AI-Driven Design and Formulations for Our First Two Microbiome Drugs!
We are thrilled to share that the European Patent Office (EPO) has approved two of our key patent applications. These patents cover the AI-driven design and the specific formulations of our first two breakthrough microbiome-based drugs.
This major milestone marks a definitive green light for securing patent protection in markets and countries worldwide, reinforcing our intellectual property and global competitive edge!
What This Means for Human Biome
-
Validation of Our Tech: It officially recognizes our unique approach to utilizing Artificial Intelligence in discovering and designing targeted microbial therapies.
-
IP Protection: It secures the proprietary compositions of our lead drug candidates as we advance them toward clinical stages.
-
Global Scaling: This European approval serves as the launchpad for global patent rollouts, protecting our innovations on a worldwide scale.
The future of medicine is microbial, intelligent, and protected. A huge congratulations to our brilliant R&D and legal teams for making this historic achievement possible!
Warsaw, March 2026
